日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验:在初诊晚期卵巢癌患者中,使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价(FZOCUS-1):一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy

肿瘤内微生物组:重塑癌症免疫疗法的双刃剑

Yan, Di; Yu, Ying; Liang, Chengtong; Cui, Zixing; Shi, Lei; Li, Guiling; Ren, Chuanli

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Suvemcitug联合化疗治疗铂类耐药复发性卵巢癌:SCORES随机、双盲、3期试验

Yuan, Guangwen; Lou, Ge; Li, Jundong; Xu, Mei; Liu, Xiaowei; Wang, Danbo; Zhang, Keqiang; Zhu, Tao; Li, Xiumin; Huang, Yi; Duan, Wei; Wang, Ke; Zhou, Qi; Li, Guiling; Yang, Chen; Zhang, Jiajing; Sun, Haolin; Tang, Renhong; Li, Qingshui; Wu, Lingying

Comparison of survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced esophageal squamous cell carcinoma

局部晚期食管鳞状细胞癌新辅助免疫化疗与化疗生存结果的比较

Sun, Yang; Yang, Hongying; Wang, Jing; Lou, Hanmei; Li, Dan; Wang, Ke; Zhang, Hui; Wu, Tao; Li, Yuzhi; Wang, Chunyan; Li, Guiling; Wang, Yifeng; Li, Dapeng; Tang, Ying; Pan, Mei; Cai, Hongyi; Wang, Weihu; Yang, Bing; Qian, Hua; Tian, Qiuhong; Yao, Desheng; Cheng, Ying; Wei, Bing; Li, Xiumin; Wang, Tao; Hao, Min; Wang, Xiaohong; Wang, Tiejun; Liu, Chang; Zhu, Hong; Zhu, Lijing; Liu, Xianling; Li, Yunxia; Chen, Lihong; Li, Qingshan; Yan, Xiaojian; Wang, Fei; Cai, Hongbing; Zhang, Yunyan; Liang, Zhiqing; Liu, Funan; Huang, Yi; Xia, Bairong; Qu, Pengpeng; Zhu, Genhai; Chen, Youguo; Song, Kun; Sun, Meili; Chen, Zhengzheng; Zhou, Qiang; Hu, Lina; Abulizi, Guzhalinuer; Guo, Hongyan; Liao, Sihai; Ye, Yijing; Yan, Ping; Tang, Qiu; Sun, Guoping; Liu, Ting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin M; Li, Baiyong; Xia, Michelle; Wu, Xiaohua; Tian, Yichun; Wang, Xian; Lu, Zhaoxin; Mi, Yaqing; Zhou, Shaobo; Xu, Weili; Wolfe, Stanley B; Wei, Lawrence; Hayanga, JW; Chauhan, Dhaval; Dans, Nestor F; Mascio, Christopher E; Rankin, J Scott; Badhwar, Vinay; Mehaffey, J Hunter; Cui, Xinrun; Wang, Yaqi; Yan, Shi; Liu, Bing; Li, Xiang; Tao, Ye; Wang, Quanne; Du, Haoxuan; Li, Shaolei; Wu, Nan

Curcumin, the Bioactive Compound of Turmeric, Boosts Cellular Antioxidant Defense via the miR-22-3p/MCAT Axis.

姜黄素是姜黄的生物活性化合物,它通过 miR-22-3p/MCAT 轴增强细胞抗氧化防御能力。

Wang Haiqi, Lin Yanqi, Li Yuanyuan, Huang Shiying, Li Guiling

Emergence of a carbapenem-resistant Klebsiella pneumoniae ST15-KL19 clone with elevated virulence potential in a tertiary hospital in China

中国某三级医院出现耐碳青霉烯类肺炎克雷伯菌ST15-KL19克隆株,该克隆株具有较高的毒力。

Li, Guiling; Zhang, Yujing; Ren, Guqi; Tian, Longlong; Jiao, Xinan; Sun, Lin; Ren, Chuanli

[Retracted] MicroRNA‑18a enhances the radiosensitivity of cervical cancer cells by promoting radiation‑induced apoptosis

[已撤稿] MicroRNA-18a 通过促进辐射诱导的细胞凋亡增强宫颈癌细胞的放射敏感性

Liu, Sha; Pan, Xiaofen; Yang, Qin; Wen, Lu; Jiang, Yao; Zhao, Yingchao; Li, Guiling

Development and evaluation of an artificial intelligence-based electrocardiogram prediction model for emergency chest pain patients

开发和评估基于人工智能的心电图预测模型,用于急诊胸痛患者

Luo, Yazhi; Peng, Juan; Peng, Wen; Zhao, Qianqian; Li, Guiling; Liu, Wanhong

Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors

一项多中心 1/2 期研究评估了双重 TORC1/2 抑制剂 onatasertib 与 PD-1 抗体 toripalimab 联合治疗晚期实体瘤的疗效。

Shu, Pei; Li, Xiaoyu; Zhou, Qi; Li, Guiling; Zhang, Keqiang; Yuan, Li; Liu, Yixian; Li, Qiu; Wang, Yongsheng; Xie, Hui; Zheng, Li

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial

呋喹替尼联合信迪利单抗治疗错配修复功能正常的晚期子宫内膜癌患者:一项多中心、单臂、Ib/II期试验

Wu, Xiaohua; Wang, Jing; Wang, Danbo; Li, Guiling; Zhang, Jieqing; Chen, Hongmin; Yang, Hongying; Zhou, Qi; Wang, Ke; Wu, Yumei; Yi, Tienan; Liu, Jihong; Huang, Yi; Bai, Yuxian; Wang, Keming; Jiang, Kui; Lou, Hanmei; An, Ruifang; Li, Xiumin; Pan, Yueyin; Wang, Yue; Tao, Weiping; Song, Kun; Kang, Yu; Li, Yuzhi; Shi, Wenyu; Liu, Anwen; Yang, Ying; Wang, Yijun; Chen, Keyan; Shi, Haiyan; Lu, Puhan; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo